ABSTRACT
Objective The lack of knowledge about the onset and progression of Parkinson’s disease (PD) hampers its early diagnosis and treatment. Our aim was to determine the biochemical remodeling induced by PD in a really early and pre-symptomatic stage and unveiling early potential diagnostic biomarkers adopting a multiplatform (LC-MS, GC-MS, CE-MS) untargeted metabolomics approach.
Methods 41,437 healthy volunteers from the European Prospective Study on Nutrition and Cancer (EPIC)-Spain cohort were followed for around 15 years to ascertain incident PD. For this study, baseline pre-clinical plasma samples of 39 randomly selected individuals (46% females, 41– 69 years old) that developed PD (Pre-PD group) and the corresponding control group (n=39, 46% females, 41–69 years old) were analyzed. The metabolic differences were investigated by univariate and multivariate data analyses, followed by pathway-based metabolite analyses to obtain possible clues on biological functions.
Results Our results exposed significantly lower levels of seven free fatty acids in the pre-PD subjects, together with alterations in other metabolite classes. Our finding revealed alterations in fatty acids metabolism, mitochondrial dysfunction, oxidative stress, and gut-brain axis dysregulation.
Conclusions Although the biological purpose of these events is still unknown, the mechanisms involved in the remodelling of the suggested metabolic pathways seem to appear long before the development of PD hallmarks. These findings might be considered as worthy potential markers whose alteration might lead to the development of PD hallmarks in the future. Consequently, this study is of inestimable value since this is the first study conducted with samples collected many years before the disease development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the following entities: Basque Government, Spain (GV2016111098), the Spanish Ministry of Science, Innovation and Universities (grant RTI2018-095166-B-I00 to C.B.), and FEDER Program 2014-2020 of the Community of Madrid (S2017/BMD3684).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate: This study was approved by the Ethics Committee for clinical research of the Basque Country PI2017031.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses: Carolina Gonzalez-Riano: carolina.gonzalezriano{at}ceu.es
Jorge Saiz: jorge.saizgalindo{at}ceu.es
Coral Barbas: cbarbas{at}ceu.es
Alberto Bergareche: JESUSALBERTO.BERGARECHEYARZA{at}osakidetza.eus
José Mª Huerta: jmhuerta.carm{at}gmail.com
Eva Ardanaz: mardanaa{at}cfnavarra.es
Marcela Konjevod: Marcela.Konjevod{at}irb.hr
Elisabet Mondragon: ELISABET.MONDRAGONREZOLA{at}osakidetza.net
ME Erro: elena.erro.aguirre{at}cfnavarra.es
M. Dolores Chirlaque: mdolores.chirlaque{at}carm.es
Eunate Abilleira: e-abilleira{at}euskadi.eus
Fernando Goñi-Irigoyen: f-goni{at}euskadi.eus
Pilar Amiano: epics-san{at}euskadi.eus
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- BA
- bile acids
- CMPF
- 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid
- DPA
- docosapentaenoic acid
- EPIC
- European Prospective Study on Nutrition and Cancer
- FFAs
- free fatty acids
- LPC
- lysoglycerophosphocholines
- MFA
- monounsaturated fatty acid
- MPP+
- 1-Methyl-4-phenylpyridinium
- MPTP
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- PC
- glycerophosphocholines
- pre-PD
- pre-Parkinson’s Disease development group
- PUFA
- polyunsaturated fatty acid
- QC-SVRC
- quality control samples and support vector regression
- RMT
- relative migration time
- SFA
- saturated fatty acid
- SVM
- Support Vector Machine.